Watching Insmed; Guggenheim Out With Note Saying "Not Very Messy After All; ARISE Delivers Clean Win In 1L MAC; Increase PT To $52, Reiterate Buy Rating; We Continue To See INSM As Best Idea"
Portfolio Pulse from Happy Mohamed
Guggenheim has released a note on Insmed, stating that the ARISE results are a clean win in 1L MAC. The firm has increased its price target for Insmed to $52 and reiterated its buy rating. Guggenheim continues to see Insmed as its best idea.
September 05, 2023 | 4:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has increased its price target for Insmed to $52 and reiterated its buy rating, indicating a positive outlook for the company.
The increase in price target and reiteration of the buy rating by Guggenheim indicates a positive outlook for Insmed. This could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100